MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice

Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilo, Nacho, Uranga, Santiago, Marinova, Dessislava, Monzon, Marta, Badiola, Juan, Martin, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Churchill Livingstone 2016
Materias:
Model Systems
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727503/
https://www.ncbi.nlm.nih.gov/pubmed/26786657
http://dx.doi.org/10.1016/j.tube.2015.10.010
_version_ 1782411974522437632
author Aguilo, Nacho
Uranga, Santiago
Marinova, Dessislava
Monzon, Marta
Badiola, Juan
Martin, Carlos
author_facet Aguilo, Nacho
Uranga, Santiago
Marinova, Dessislava
Monzon, Marta
Badiola, Juan
Martin, Carlos
author_sort Aguilo, Nacho
collection PubMed
description Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
format Online
Article
Text
id pubmed-4727503
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Churchill Livingstone
record_format MEDLINE/PubMed
spelling pubmed-47275032016-02-22 MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice Aguilo, Nacho Uranga, Santiago Marinova, Dessislava Monzon, Marta Badiola, Juan Martin, Carlos Tuberculosis (Edinb) Model Systems Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG. Churchill Livingstone 2016-01 /pmc/articles/PMC4727503/ /pubmed/26786657 http://dx.doi.org/10.1016/j.tube.2015.10.010 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Model Systems
Aguilo, Nacho
Uranga, Santiago
Marinova, Dessislava
Monzon, Marta
Badiola, Juan
Martin, Carlos
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title_full MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title_fullStr MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title_full_unstemmed MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title_short MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
title_sort mtbvac vaccine is safe, immunogenic and confers protective efficacy against mycobacterium tuberculosis in newborn mice
topic Model Systems
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727503/
https://www.ncbi.nlm.nih.gov/pubmed/26786657
http://dx.doi.org/10.1016/j.tube.2015.10.010
work_keys_str_mv AT aguilonacho mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice
AT urangasantiago mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice
AT marinovadessislava mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice
AT monzonmarta mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice
AT badiolajuan mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice
AT martincarlos mtbvacvaccineissafeimmunogenicandconfersprotectiveefficacyagainstmycobacteriumtuberculosisinnewbornmice

Ejemplares similares